Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

References

• Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol 1988; 27: 699–705
   PubMed Web of Science ®Google Scholar
• Anonymous. Controlled trial of Tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985; 1(8433)836–40
   PubMedGoogle Scholar
• Anonymous. Adjuvant Tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987; 2(8552)171–5
   PubMedGoogle Scholar
• Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988; 27: 721–8
   PubMed Web of Science ®Google Scholar
• Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Bormer O, et al. Cyclical use of Tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 1990; 17: 45–50
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant Tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543–9
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus Tamoxifen after 2-3 years' Tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007; 369(9561)559–70
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant Tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366(9484)455–62
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after Tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399–411
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453–61
   PubMed Web of Science ®Google Scholar
• Fjosne HE, Jacobsen AB, Lundgren S. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients—Long-term follow-up. Eur J Surg Oncol 2007.
   PubMedGoogle Scholar
• Rose C, Andersen JA, Andersen KW, Axelsson CK, Blichert-Toft M, Dombernowsky P, et al. Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial. Ugeskr Laeger 1991; 153: 2283–7
   PubMedGoogle Scholar
• Focan C, Beauduin M, Majois F, Canon JL, Cusumano G, Focan-Henrard D, et al. High-dose oral medroxyprogesterone acetate or Tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: Randomized trial with 7-year update. Clin Breast Cancer 2004; 5: 136–41
   PubMedGoogle Scholar
• Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001; 1:CD000486.
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339(8784)1–15
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of Tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42
   PubMed Web of Science ®Google Scholar